Xbrane Biopharma AB (publ)
SSE:XBRANE.ST
Overview | Financials
Company Name | Xbrane Biopharma AB (publ) |
Symbol | XBRANE.ST |
Currency | SEK |
Price | 2.085 |
Market Cap | 61,989,344 |
Dividend Yield | 0% |
52-week-range | 1.19 - 104.2 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Siavash Bashiri |
Website | https://www.xbrane.com |
An error occurred while fetching data.
About Xbrane Biopharma AB (publ)
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD